277 related articles for article (PubMed ID: 25762343)
1. CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.
Birzele F; Voss E; Nopora A; Honold K; Heil F; Lohmann S; Verheul H; Le Tourneau C; Delord JP; van Herpen C; Mahalingam D; Coveler AL; Meresse V; Weigand S; Runza V; Cannarile M
Clin Cancer Res; 2015 Jun; 21(12):2753-62. PubMed ID: 25762343
[TBL] [Abstract][Full Text] [Related]
2. First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.
Menke-van der Houven van Oordt CW; Gomez-Roca C; van Herpen C; Coveler AL; Mahalingam D; Verheul HM; van der Graaf WT; Christen R; Rüttinger D; Weigand S; Cannarile MA; Heil F; Brewster M; Walz AC; Nayak TK; Guarin E; Meresse V; Le Tourneau C
Oncotarget; 2016 Nov; 7(48):80046-80058. PubMed ID: 27507056
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies.
Vugts DJ; Heuveling DA; Stigter-van Walsum M; Weigand S; Bergstrom M; van Dongen GA; Nayak TK
MAbs; 2014; 6(2):567-75. PubMed ID: 24492295
[TBL] [Abstract][Full Text] [Related]
4. Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist.
Weigand S; Herting F; Maisel D; Nopora A; Voss E; Schaab C; Klammer M; Tebbe A
Cancer Res; 2012 Sep; 72(17):4329-39. PubMed ID: 22777824
[TBL] [Abstract][Full Text] [Related]
5. Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer.
Karousou E; Misra S; Ghatak S; Dobra K; Götte M; Vigetti D; Passi A; Karamanos NK; Skandalis SS
Matrix Biol; 2017 May; 59():3-22. PubMed ID: 27746219
[TBL] [Abstract][Full Text] [Related]
6. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.
Bjorklund CC; Baladandayuthapani V; Lin HY; Jones RJ; Kuiatse I; Wang H; Yang J; Shah JJ; Thomas SK; Wang M; Weber DM; Orlowski RZ
Leukemia; 2014 Feb; 28(2):373-83. PubMed ID: 23760401
[TBL] [Abstract][Full Text] [Related]
7. Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer.
Miwa T; Nagata T; Kojima H; Sekine S; Okumura T
Int J Oncol; 2017 Sep; 51(3):771-780. PubMed ID: 28677740
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells.
Masuko K; Okazaki S; Satoh M; Tanaka G; Ikeda T; Torii R; Ueda E; Nakano T; Danbayashi M; Tsuruoka T; Ohno Y; Yagi H; Yabe N; Yoshida H; Tahara T; Kataoka S; Oshino T; Shindo T; Niwa S; Ishimoto T; Baba H; Hashimoto Y; Saya H; Masuko T
PLoS One; 2012; 7(1):e29728. PubMed ID: 22272243
[TBL] [Abstract][Full Text] [Related]
9. Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells.
Harada N; Mizoi T; Kinouchi M; Hoshi K; Ishii S; Shiiba K; Sasaki I; Matsuno S
Int J Cancer; 2001 Jan; 91(1):67-75. PubMed ID: 11149422
[TBL] [Abstract][Full Text] [Related]
10. 4-Methylumbelliferone Suppresses Hyaluronan Synthesis and Tumor Progression in SCID Mice Intra-abdominally Inoculated With Pancreatic Cancer Cells.
Nagase H; Kudo D; Suto A; Yoshida E; Suto S; Negishi M; Kakizaki I; Hakamada K
Pancreas; 2017 Feb; 46(2):190-197. PubMed ID: 27846148
[TBL] [Abstract][Full Text] [Related]
11. CD44 activation state regulated by the CD44v10 isoform determines breast cancer proliferation.
Guo Q; Liu Y; He Y; Du Y; Zhang G; Yang C; Gao F
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649828
[TBL] [Abstract][Full Text] [Related]
12. CD44 mediates the catch-bond activated rolling of HEPG2Iso epithelial cancer cells on hyaluronan.
Hanke-Roos M; Fuchs K; Maleschlijski S; Sleeman J; Orian-Rousseau V; Rosenhahn A
Cell Adh Migr; 2017 Sep; 11(5-6):476-487. PubMed ID: 27874296
[TBL] [Abstract][Full Text] [Related]
13. The Role of CD44 and Cancer Stem Cells.
Wang L; Zuo X; Xie K; Wei D
Methods Mol Biol; 2018; 1692():31-42. PubMed ID: 28986884
[TBL] [Abstract][Full Text] [Related]
14. Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells.
Welsh CF; Zhu D; Bourguignon LY
J Cell Physiol; 1995 Sep; 164(3):605-12. PubMed ID: 7544357
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9-mediated silencing of CD44: unveiling the role of hyaluronic acid-mediated interactions in cancer drug resistance.
Xu Z
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):2849-2876. PubMed ID: 37991544
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the Efficiency of Hyaluronic Acid for Tumor Targeting via CD44.
Spadea A; Rios de la Rosa JM; Tirella A; Ashford MB; Williams KJ; Stratford IJ; Tirelli N; Mehibel M
Mol Pharm; 2019 Jun; 16(6):2481-2493. PubMed ID: 31013093
[TBL] [Abstract][Full Text] [Related]
17. CD44 as a marker in human cancers.
Sy MS; Mori H; Liu D
Curr Opin Oncol; 1997 Jan; 9(1):108-12. PubMed ID: 9090502
[TBL] [Abstract][Full Text] [Related]
18. A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells.
Piotrowicz RS; Damaj BB; Hachicha M; Incardona F; Howell SB; Finlayson M
Mol Cancer Ther; 2011 Nov; 10(11):2072-82. PubMed ID: 21885863
[TBL] [Abstract][Full Text] [Related]
19. Oncogene-dependent expression of CD44 in Balb/c 3T3 derivatives: correlation with metastatic competence.
Kogerman P; Sy MS; Culp LA
Clin Exp Metastasis; 1996 Jan; 14(1):73-82. PubMed ID: 8521619
[TBL] [Abstract][Full Text] [Related]
20. CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression.
Bourguignon LY; Zhu D; Zhu H
Front Biosci; 1998 Jul; 3():d637-49. PubMed ID: 9634539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
